KIRIN-HOLDINGS
5.8.2022 04:02:10 CEST | Business Wire | Press release
Kirin Holdings Company, Limited (Kirin Holdings) has been approved as the first world company in the food and beverage processing sector with science-based net-zero targets validated by SBTi * 2 in July 2022. The Kirin Group’s long-term GHG reduction target , "realizing net-zero* 3 GHG* 4 emission from the entire value chain by 2050" set forth in the Kirin Group Environmental Vision 2050 was certified as a scientifically based goal consistent with the level of GHG emission reductions required by the Paris Agreement* 5 .
Kirin Holdings, with the aim of becoming " A global leader in CSV* 6 ”, have declared our goal of achieving net-zero emissions by 2020 under the Kirin Group Environmental Vision 2050 and have formulated a roadmap for achieving the goal, which went into operation in January 2022.
A sense of crisis was shared around the world on the issue of climate change in the wake of the 2015 Paris Agreement, the 2018 IPCC 1.5°C Special Report* 7 reported that global warming from pre-industrial times must be limited to 1.5°C and GHG emissions must be reduced to net zero by around 2050. In order to achieve that common global long-term goal, many companies in the world have set "2050 Net Zero" targets. However, since there is no common standard for corporate net-zero targets, the scope of GHG emissions to be covered, the means to achieve net-zero, and the level of GHG reductions differ, and thus a divergence from the target needed to limit global warming to 1.5°C has been pointed out.
In response to this flurry of net-zero targets, the SBT Initiative developed the "Net Zero Standard" in October 2021. This standard stipulates that in order to limit global warming to 1.5°C, companies must reduce GHG emissions by at least 90% across their value chains by 2050, and the net-zero can be achieved by removing the remaining 10% of GHG emissions from the atmosphere.
In order to achieve The Kirin Group’s long-term goal, Kirin Holdings has set a mid-term target for 2030 (to reduce the total of Scope 1 and Scope 2 for the entire group by 50% and Scope 3 by 30% by 2030 compared to 2019), and is promoting GHG reduction in our value chain with the technological capabilities we have cultivated over the years. For Scope 1 and Scope 2, we have installed heat pumps at six Kirin Brewery breweries in Japan, utilizing our plant engineering capabilities to reduce GHG emissions by approximately 3,800 tons per year. In terms of Scope 3, we are gradually expanding the use of "R100 PET bottles" made of 100% recycled PET resin, and are rolling them out for some of our Kirin Nama-cha brands.
With the goal of achieving net zero emissions by 2050, Kirin Holdings will continue to work toward the realization of the Kirin Group Environmental Vision 2050, which aims to strengthen the resilience of society and the company, and to lead the way toward the creation of a decarbonized society.
1: |
Science Based Targets: Greenhouse gas reduction targets based on scientific evidence. |
2: |
An international initiative jointly established in 2015 by CDP, the UN Global Compact, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). |
3: |
A state in which anthropogenic GHG emissions and removals are balanced and GHG emissions to the atmosphere are net zero. |
4: |
Green House Gas |
5: |
International framework for global warming countermeasures in which all countries and regions participate |
6: |
Creating Shared Value. Combined added value for consumers as well as for society at large. |
7: |
This report published by the Intergovernmental Panel on Climate Change (IPCC) describes the significant difference between 2°C and 1.5°C in terms of the impact of future temperature increases and the emission pathways to limit the increase to 1.5°C. |
[Reference]
・Kirin Group Environmental Vision 2050
https://www.kirinholdings.com/en/impact/env/mission/
About Kirin Holdings
Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005519/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
